These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 32719309)

  • 1. [Comparison of hospital consumption of immediate-release fentanyl: use or abuse?].
    Arrieta Loitegui M; Caro Teller JM; Rosas Espinoza C; Ferrari Piquero JM
    Rev Esp Salud Publica; 2020 Jul; 94():. PubMed ID: 32719309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Prevalence of Off-label Prescribing of Transmucosal Immediate-Release Fentanyl in France.
    Guastella V; Delorme J; Chenaf C; Authier N
    J Pain Symptom Manage; 2022 Jun; 63(6):980-987. PubMed ID: 35192879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Rapid release fentanyl administration forms. Comments of the Working Group on Tumor Pain of the German Pain Society].
    Wirz S; Wiese CH; Zimmermann M; Junker U; Heuser-Grannemann E; Schenk M
    Schmerz; 2013 Feb; 27(1):76-80. PubMed ID: 23377349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products.
    Rollman JE; Heyward J; Olson L; Lurie P; Sharfstein J; Alexander GC
    JAMA; 2019 Feb; 321(7):676-685. PubMed ID: 30778596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immediate release fentanyl in general practices: Mostly off-label prescribing.
    Weesie YM; van Dijk L; Bouvy ML; Hek K
    Eur J Gen Pract; 2023 Dec; 29(1):2165644. PubMed ID: 36695153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in trends and pattern of strong opioid prescribing in primary care.
    Zin CS; Chen LC; Knaggs RD
    Eur J Pain; 2014 Oct; 18(9):1343-51. PubMed ID: 24756859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant drug-related behavior observed during a 12-week open-label extension period of a study involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet or traditional short-acting opioid for breakthrough pain.
    Passik SD; Narayana A; Yang R
    Pain Med; 2014 Aug; 15(8):1365-72. PubMed ID: 24666664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in consumption of opioid analgesics in Israel 2009 to 2016: An update focusing on oxycodone and fentanyl formulations.
    Ponizovsky AM; Marom E; Weizman A; Schwartzberg E
    Pharmacoepidemiol Drug Saf; 2018 May; 27(5):535-540. PubMed ID: 29488288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fentanyl for breakthrough pain: a systematic review.
    Davis MP
    Expert Rev Neurother; 2011 Aug; 11(8):1197-216. PubMed ID: 21797660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.
    Alberts DS; Smith CC; Parikh N; Rauck RL
    Pain Manag; 2016 Oct; 6(5):427-34. PubMed ID: 27020837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic cancer and noncancer pain: a randomized, double-blind, crossover study followed by a 12-week open-label phase to evaluate patient outcomes.
    Webster LR; Slevin KA; Narayana A; Earl CQ; Yang R
    Pain Med; 2013 Sep; 14(9):1332-45. PubMed ID: 23855816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015.
    Vijay A; Rhee TG; Ross JS
    Prev Med; 2019 Jun; 123():123-129. PubMed ID: 30894321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On-label and off-label prescribing patterns of erythropoiesis-stimulating agents in inpatient hospital settings in the US during the period of major regulatory changes.
    Seetasith A; Holdford D; Shah A; Patterson J
    Res Social Adm Pharm; 2017; 13(4):778-788. PubMed ID: 27595426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging opioid abuse in terminal cancer patients taking oral transmucosal fentanyl citrate for breakthrough pain.
    Núñez-Olarte JM; Alvarez-Jiménez P
    J Pain Symptom Manage; 2011 Dec; 42(6):e6-8. PubMed ID: 22048003
    [No Abstract]   [Full Text] [Related]  

  • 15. Aberrant drug-related behavior observed during clinical studies involving patients taking chronic opioid therapy for persistent pain and fentanyl buccal tablet for breakthrough pain.
    Passik SD; Messina J; Golsorkhi A; Xie F
    J Pain Symptom Manage; 2011 Jan; 41(1):116-25. PubMed ID: 20580202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Novotna S; Valentova K; Fricova J; Richterova E; Harabisova S; Bullier F; Trinquet F;
    Clin Ther; 2014 Mar; 36(3):357-67. PubMed ID: 24508417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of Risk Minimization Measures for Fentanyl Buccal Tablet (FENTORA) in Canada: A Mixed-Methods Evaluation Using Surveys, Medical Chart Records and Web Surveillance.
    Kaplan S; Bergamasco A; Sergerie M; Castilloux AM; Moride Y
    Drug Saf; 2020 Feb; 43(2):163-177. PubMed ID: 31691255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
    Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
    Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids for the management of breakthrough pain in cancer patients.
    Zeppetella G; Davies AN
    Cochrane Database Syst Rev; 2013 Oct; (10):CD004311. PubMed ID: 24142465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized, placebo-controlled study of a new sublingual formulation of fentanyl citrate (fentanyl ethypharm) for breakthrough pain in opioid-treated patients with cancer.
    Gombert-Handoko KB
    Clin Ther; 2014 Nov; 36(11):1704. PubMed ID: 25048312
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.